Stem Cells From Human Exfoliated Teeth in Treatment of Diabetic Patients With Significantly Reduced Islet Function
Stem Cells From Human Exfoliated Teeth in Treatment of Diabetic Patients With Significantly Reduced Islet Function
To evaluate the safety and efficacy of Stem cells from human exfoliated teeth transplantation
 in patients with Islet function decreased significantly to provides scientific basis for
 further clinical studies to verify the safety and efficacy. On the basis of maintaining the
 original treatment, intravenous drip of dental pulp mesenchymal stem cells.
Basic treatment:

 The original treatment regimen was maintained. During the study period, insulin dose could be
 adjusted with the change of blood glucose, while the type and dose of oral hypoglycemic drugs
 remained unchanged (except when side effects of drugs or insulin preparations were stopped or
 patients still had frequent hypoglycemia).

 Stem cell therapy:

 Dosage: Stem cells from human exfoliated teeth were calculated at 0.11IU/kg body weight .

 Course of treatment: 3 times, Injections were administered at enrollment, 2 weeks after
 enrollment, and 6 weeks after enrollment.

 Note: at 1 month follow-up (V5) after the last transplantation of several cells, the subjects
 were still unable to discontinue insulin, and then began the second course of stem cell
 therapy.After the second course of treatment, the follow-up plan was resumed.
Inclusion Criteria:

 1. Understand the purpose of clinical trials, willing to participate and sign informed
 consent;

 2. Patients with type 2 diabetes are clearly diagnosed according to WHO diagnostic
 criteria and whose disease duration is more than 5 years, or whose disease duration of
 type 1 diabetes is more than 1 year;

 3. Islet function test (steamed bread test) : c-peptide fasting 1ng/ml, 2 hours 2ng/ml

 4. Insulin (with or without oral hypoglycemic therapy) and fasting blood glucose
 (FPG)9.0mmol/L, HbAlc 8.5; The service life of oral hypoglycemic drugs (including
 metformin, alpha-glucosidase inhibitors or insulin secreting agents) was more than 3
 months.

 5. Age 25-70 years old, gender not limited;

 6. Body mass index (BMI) : between 19 and 28kg/m2;

 7. from the date of screening to the end of follow-up, male or female subjects of
 childbearing age will voluntarily take precautions Pregnancy; Urine pregnancy test was
 negative when screening women of childbearing age, and serum pregnancy test was
 performed when necessary to clearly exclude pregnancy.-

 Exclusion Criteria:

 1. Patients with gestational diabetes or other special types of diabetes;

 2. Acute complications such as diabetic ketoacidosis and non-ketotic hyperosmolar
 syndrome were screened within the first month;

 3. Patients who have received other stem cell therapy before screening;

 4. Blood pressure of patients with poor blood pressure control: 160/100mmhg at the time
 of screening;

 5. Those who took thiazolidinediones, ddp-iv inhibitors and glp-1 drugs within the first
 3 months were screened;

 6. Patients who have used insulin for less than 1 year before screening and only injected
 insulin subcutaneously once a day within the past 3 months;

 7. Patients with pancreatic diseases, including those with acute and chronic pancreatitis
 and pancreatic tumors;

 8. Patients with other malignant tumors or suspected tumor tendency;Or in the active
 phase of various infections (including active stage of HBV or HCV
 infection);Immunodeficiency virus (HIV) positive patients;

 9. Patients with other serious systemic diseases (such as cardiovascular system,
 respiratory system, digestive system, nervous system, endocrine system, urogenital
 system, immune system and blood system);

 10. For patients with liver and kidney dysfunction, for example, serum bilirubin TBIL
 exceeds 1.5 times of the normal upper limit, AST and ALT exceed 2.5 times of the
 normal upper limit, and serum creatinine Cr exceeds 1.2 times of the normal upper
 limit;

 11. Is on systemic sex hormone (glucocorticoid), immunosuppressant or cytotoxic therapy;

 12. Disabled patients (blind, deaf, dumb, mentally retarded, physically disabled) as
 stipulated by law, pregnant women and lactating women;People suffering from mental
 illness;Patients who take drugs or have a history of adverse drug abuse and alcohol
 dependence within 5 years;

 13. Patients with contraindications or allergies treated in this study;

 14. Subjects who have participated in other clinical studies in the past 3 months.